Cargando…

Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study

BACKGROUND: The WHO VISION 2020 global initiative against blindness, launched in 2000, prioritised childhood visual disability by aiming to end avoidable childhood blindness by 2020. However, progress has been hampered by the global paucity of epidemiological data concerning childhood visual disabil...

Descripción completa

Detalles Bibliográficos
Autores principales: Teoh, Lucinda J, Solebo, Ameenat Lola, Rahi, Jugnoo S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765867/
https://www.ncbi.nlm.nih.gov/pubmed/33524322
http://dx.doi.org/10.1016/S2352-4642(20)30366-7
_version_ 1784853591596466176
author Teoh, Lucinda J
Solebo, Ameenat Lola
Rahi, Jugnoo S
author_facet Teoh, Lucinda J
Solebo, Ameenat Lola
Rahi, Jugnoo S
author_sort Teoh, Lucinda J
collection PubMed
description BACKGROUND: The WHO VISION 2020 global initiative against blindness, launched in 2000, prioritised childhood visual disability by aiming to end avoidable childhood blindness by 2020. However, progress has been hampered by the global paucity of epidemiological data concerning childhood visual disability. The British Childhood Visual Impairment and Blindness Study 2 (BCVIS2) was done to address this evidence gap. METHODS: BCVIS2 was a prospective UK-wide, cross-sectional, observational study to establish an inception cohort of children newly diagnosed with visual impairment. Ophthalmologists and paediatricians reported cases from 89 hospitals and community centres across the UK. We included children aged 18 years or younger who were newly diagnosed with any condition causing impaired visual acuity to a level of 0·5 logMAR or worse (worse than 6/18 Snellen) in each eye, or equivalent vision as assessed by standard qualitative measures, between Oct 1, 2015, and Nov 1, 2016. Eligible children were notified simultaneously but independently by their managing ophthalmologists and paediatricians via the two national active surveillance schemes, the British Ophthalmological Surveillance Unit and the British Paediatric Surveillance Unit. Standardised detailed demographic, socioeconomic, and clinical data about detection, management, and treatment were collected at diagnosis and 1 year later. We calculated incidence estimates and relative rates by key sociodemographic factors. We did descriptive analyses of underlying ophthalmic disorders and non-ophthalmic comorbidities. FINDINGS: 61 (7%) of 845 eligible children initially notified were ineligible at follow-up because of improved vision after treatment. Thus, the study sample comprised 784 children with permanent newly-diagnosed all-cause visual impairment, severe visual impairment, or blindness. 559 (72%) of 778 children had clinically significant non-ophthalmic impairments or conditions. 28 (4%) of 784 children died within a year after diagnosis of visual disability (all had underlying systemic disorders). Incidence of visual disability in the first year of life was 5·19 per 10 000 children (95% CI 4·71–5·72), almost ten times higher than among 1-to-4-year-olds and between 20 times and 100 times higher than in the older age groups. The overall cumulative incidence (or lifetime risk) of visual impairment, severe visual impairment, or blindness was 10·03 per 10 000 children (9·35–10·76). Incidence rates were higher for those from any ethnic minority group, the lowest quintile of socioeconomic status, and those born preterm or with low birthweight. 345 (44%) of 784 children had a single affected anatomical site. Disorders of the brain and visual pathways affected 378 (48%) of 784 children. INTERPRETATION: BCVIS2 provides a contemporary snapshot of the heterogeneity, multi-morbidity, and vulnerability associated with childhood visual disability in a high-income country. These findings could facilitate developing and delivering health care and planning of interventional research. Our findings highlight the importance of including childhood visual disability as a sentinel event and metric in global child health initiatives. FUNDING: Fight for Sight, National Institute for Health Research, and Ulverscroft Foundation.
format Online
Article
Text
id pubmed-9765867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97658672022-12-21 Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study Teoh, Lucinda J Solebo, Ameenat Lola Rahi, Jugnoo S Lancet Child Adolesc Health Articles BACKGROUND: The WHO VISION 2020 global initiative against blindness, launched in 2000, prioritised childhood visual disability by aiming to end avoidable childhood blindness by 2020. However, progress has been hampered by the global paucity of epidemiological data concerning childhood visual disability. The British Childhood Visual Impairment and Blindness Study 2 (BCVIS2) was done to address this evidence gap. METHODS: BCVIS2 was a prospective UK-wide, cross-sectional, observational study to establish an inception cohort of children newly diagnosed with visual impairment. Ophthalmologists and paediatricians reported cases from 89 hospitals and community centres across the UK. We included children aged 18 years or younger who were newly diagnosed with any condition causing impaired visual acuity to a level of 0·5 logMAR or worse (worse than 6/18 Snellen) in each eye, or equivalent vision as assessed by standard qualitative measures, between Oct 1, 2015, and Nov 1, 2016. Eligible children were notified simultaneously but independently by their managing ophthalmologists and paediatricians via the two national active surveillance schemes, the British Ophthalmological Surveillance Unit and the British Paediatric Surveillance Unit. Standardised detailed demographic, socioeconomic, and clinical data about detection, management, and treatment were collected at diagnosis and 1 year later. We calculated incidence estimates and relative rates by key sociodemographic factors. We did descriptive analyses of underlying ophthalmic disorders and non-ophthalmic comorbidities. FINDINGS: 61 (7%) of 845 eligible children initially notified were ineligible at follow-up because of improved vision after treatment. Thus, the study sample comprised 784 children with permanent newly-diagnosed all-cause visual impairment, severe visual impairment, or blindness. 559 (72%) of 778 children had clinically significant non-ophthalmic impairments or conditions. 28 (4%) of 784 children died within a year after diagnosis of visual disability (all had underlying systemic disorders). Incidence of visual disability in the first year of life was 5·19 per 10 000 children (95% CI 4·71–5·72), almost ten times higher than among 1-to-4-year-olds and between 20 times and 100 times higher than in the older age groups. The overall cumulative incidence (or lifetime risk) of visual impairment, severe visual impairment, or blindness was 10·03 per 10 000 children (9·35–10·76). Incidence rates were higher for those from any ethnic minority group, the lowest quintile of socioeconomic status, and those born preterm or with low birthweight. 345 (44%) of 784 children had a single affected anatomical site. Disorders of the brain and visual pathways affected 378 (48%) of 784 children. INTERPRETATION: BCVIS2 provides a contemporary snapshot of the heterogeneity, multi-morbidity, and vulnerability associated with childhood visual disability in a high-income country. These findings could facilitate developing and delivering health care and planning of interventional research. Our findings highlight the importance of including childhood visual disability as a sentinel event and metric in global child health initiatives. FUNDING: Fight for Sight, National Institute for Health Research, and Ulverscroft Foundation. Elsevier Ltd. 2021-03 2021-01-29 /pmc/articles/PMC9765867/ /pubmed/33524322 http://dx.doi.org/10.1016/S2352-4642(20)30366-7 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Articles
Teoh, Lucinda J
Solebo, Ameenat Lola
Rahi, Jugnoo S
Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study
title Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study
title_full Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study
title_fullStr Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study
title_full_unstemmed Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study
title_short Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study
title_sort visual impairment, severe visual impairment, and blindness in children in britain (bcvis2): a national observational study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765867/
https://www.ncbi.nlm.nih.gov/pubmed/33524322
http://dx.doi.org/10.1016/S2352-4642(20)30366-7
work_keys_str_mv AT teohlucindaj visualimpairmentseverevisualimpairmentandblindnessinchildreninbritainbcvis2anationalobservationalstudy
AT soleboameenatlola visualimpairmentseverevisualimpairmentandblindnessinchildreninbritainbcvis2anationalobservationalstudy
AT rahijugnoos visualimpairmentseverevisualimpairmentandblindnessinchildreninbritainbcvis2anationalobservationalstudy
AT visualimpairmentseverevisualimpairmentandblindnessinchildreninbritainbcvis2anationalobservationalstudy